Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes (6:00).
06-27-2021 | ADA 2021 | Conference coverage | Video
06-27-2021 | ADA 2021 | Conference coverage | Video
Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes (6:00).